These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 25820336)

  • 21. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
    Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
    Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
    Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
    Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.
    Hullmann JE; Grisanti LA; Makarewich CA; Gao E; Gold JI; Chuprun JK; Tilley DG; Houser SR; Koch WJ
    Circ Res; 2014 Dec; 115(12):976-85. PubMed ID: 25332207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779.
    Lin H; Zhu Y; Zheng C; Hu D; Ma S; Chen L; Wang Q; Chen Z; Xie J; Yan Y; Huang X; Liao W; Kitakaze M; Bin J; Liao Y
    Circulation; 2021 Jun; 143(23):2277-2292. PubMed ID: 33757294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of adenosine A1 receptor attenuates tumor necrosis factor-α induced hypertrophy of cardiomyocytes.
    Liao Y; Lin L; Lu D; Fu Y; Bin J; Xu D; Kitakaze M
    Biomed Pharmacother; 2011 Oct; 65(7):491-5. PubMed ID: 21993001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S100A8/MYD88/NF-қB: a novel pathway involved in cardiomyocyte hypertrophy driven by thyroid hormone.
    Takano APC; Munhoz CD; Moriscot AS; Gupta S; Barreto-Chaves MLM
    J Mol Med (Berl); 2017 Jun; 95(6):671-682. PubMed ID: 28161820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transfection by eukaryotic expression vector pcDNA3-HERG inhibits the cultured neonatal rabbit ventricular myocyte hypertrophy induced by phenylephrine.
    Zhao Y; Xu Y; Cui C; Li Y; Zeng Y
    Cardiovasc Pathol; 2012; 21(4):339-45. PubMed ID: 22100990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis.
    Lebeche D; Kaprielian R; del Monte F; Tomaselli G; Gwathmey JK; Schwartz A; Hajjar RJ
    Circulation; 2004 Nov; 110(22):3435-43. PubMed ID: 15557376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.
    Guo J; Mihic A; Wu J; Zhang Y; Singh K; Dhingra S; Weisel RD; Li RK
    Eur Heart J; 2015 Oct; 36(37):2530-40. PubMed ID: 26160001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
    Braz JC; Bueno OF; Liang Q; Wilkins BJ; Dai YS; Parsons S; Braunwart J; Glascock BJ; Klevitsky R; Kimball TF; Hewett TE; Molkentin JD
    J Clin Invest; 2003 May; 111(10):1475-86. PubMed ID: 12750397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
    Gesmundo I; Miragoli M; Carullo P; Trovato L; Larcher V; Di Pasquale E; Brancaccio M; Mazzola M; Villanova T; Sorge M; Taliano M; Gallo MP; Alloatti G; Penna C; Hare JM; Ghigo E; Schally AV; Condorelli G; Granata R
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12033-12038. PubMed ID: 29078377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
    Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
    Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The elevated serum S100A8/A9 during acute myocardial infarction is not of cardiac myocyte origin.
    Du CQ; Yang L; Han J; Yang J; Yao XY; Hu XS; Hu SJ
    Inflammation; 2012 Jun; 35(3):787-96. PubMed ID: 21887593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling.
    Volz HC; Laohachewin D; Seidel C; Lasitschka F; Keilbach K; Wienbrandt AR; Andrassy J; Bierhaus A; Kaya Z; Katus HA; Andrassy M
    Basic Res Cardiol; 2012 Mar; 107(2):250. PubMed ID: 22318783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure.
    Ohtani T; Mano T; Hikoso S; Sakata Y; Nishio M; Takeda Y; Otsu K; Miwa T; Masuyama T; Hori M; Yamamoto K
    J Hypertens; 2009 May; 27(5):1074-83. PubMed ID: 19349910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. lncRNA UCA1 Is a Novel Regulator in Cardiomyocyte Hypertrophy through Targeting the miR-184/HOXA9 Axis.
    Zhou G; Li C; Feng J; Zhang J; Fang Y
    Cardiorenal Med; 2018; 8(2):130-139. PubMed ID: 29616999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiomyocyte-enriched protein CIP protects against pathophysiological stresses and regulates cardiac homeostasis.
    Huang ZP; Kataoka M; Chen J; Wu G; Ding J; Nie M; Lin Z; Liu J; Hu X; Ma L; Zhou B; Wakimoto H; Zeng C; Kyselovic J; Deng ZL; Seidman CE; Seidman JG; Pu WT; Wang DZ
    J Clin Invest; 2015 Nov; 125(11):4122-34. PubMed ID: 26436652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
    Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
    Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
    Liao Y; Takashima S; Zhao H; Asano Y; Shintani Y; Minamino T; Kim J; Fujita M; Hori M; Kitakaze M
    Cardiovasc Res; 2006 Apr; 70(1):107-16. PubMed ID: 16510136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.